First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
PMID: 32843050
2020
Antimicrobial resistance and infection control
Conclusion: Another GRT, covering HIV-1 integrase (IN) region, performed on the sample plasma aliquot, revealed major RAMs, L74I, E138KQ, G140A, Q148R, and E157Q, to integrase strand transfer inhibitors (INSTI) including raltegravir, dolutegravir, bictegravir and elvitegravir.
Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naive HIV-1-Infected Adults in Guangdong Province, China, in 2018.
Abstract: Among them, no major resistance mutations to INSTIs were identified, and four accessory mutations, including T97A (0.12%, 1/827),
Conclusion: In conclusion, our results demonstrate that drug resistance mutations associated with INSTIs, including T97A, A128T, E157Q, and G163R, were detected among ART-naive HIV-1-infected adults in Guangdong, China, in 2018.
Result: The mutations were T97A (0.12%, 1/827), A128T (0.24%, 2/827), E157Q (0.85%, 7/827), and G163R (0.24%, 2/827).
Table: E157Q
Circulating HIV-1 Integrase Genotypes in Tanzania: Implication on the Introduction of Integrase Inhibitors-Based Antiretroviral Therapy Regimen.
PMID: 32126792
2020
AIDS research and human retroviruses
Abstract: No major INSTI resistance mutations were found; however, accessory resistance mutations at positions T97A, E157Q, G163E/K, and 128A/T were detected in 5% of subjects.
Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya.
PMID: 32116431
2020
Ethiopian journal of health sciences
Abstract: However, polymorphic accessory mutations associated with reduced susceptibility of integrase inhibitors were observed in low frequency; M50I (12.2%), T97A (3.7%), S153YG, E92G (1.6%), G140S/A/C (1.1%) and E157Q (0.5%).
Result: These mutations were M50I (12.2%), T97A (3.7%), S153YG, E92G (1.6%), G140S/A/C (1.1%) and E157Q (0.5%).
Table: E157Q
Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy.
PMID: 32106437
2020
International journal of molecular sciences
Result: E157Q and S119R mutations were observed only in cohort samples of AG subtype.
Result: The INSTIs accessory RAMs E157Q and T97A were present, respectively, in 6 (all CRF02_AG) and 2 (1 CRF02_AG and 1 CRF09_cpx) samples (Table 2).
Result: The INSTIs accessory RAMs identified in both AG and AG database samples included T97A, E157Q, M50I, L74M, L74I, and S230N (in 3.5% to 60% of AG and in 1.4% to 86.5% of non-AG database samples).
Result: The INSTIs accessory RAMs identified in both cohort and database samples
High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.
PMID: 32105319
2020
The Journal of antimicrobial chemotherapy
Result: The most common integrase polymorphism was E157Q, which was detected in 12 participants (6 of these also had L74I).
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Result: However, one sample (subject 13) had the presence of the E157Q substitution (Table 2).
Table: E157Q
Discussion: More information is needed to further recommend the use of DTG in naive patients harbouring the E157Q substitution as suggested by Charpentier and Descamps.
Discussion: The E157Q substitution (found in subject 13) is a natural polymorphism described as a compensatory mutation for R263K-mediated DTG resistance and after RAL exposure.
Analyses of HIV-1 integrase gene sequences among treatment-naive patients in the Eastern Cape, South Africa.
Abstract: However, E157Q (2.1%), L74M/I (4.2%), and P142T (2.1%) were the observed accessory and polymorphic mutations.
HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms Among Integrase Strand Transfer Inhibitor-Naive HIV-1 Patients from Cameroon.
PMID: 31830799
2020
AIDS research and human retroviruses
Abstract: Accessory RAMs were present in 8.1% (n = 3/37) of the sequences, of which one sequence contained solely E157Q, and another Q95K.
Abstract: One patient sequence had three accessory RAMs (G140E, E157Q, and G163R).
Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
Abstract: The accessory RAM E157Q was identified in two (2.2%).
Result: The mutation identified and classified as an 'accessory' integrase, E157Q, occurred in two (2%
Discussion: A study has shown that eight patients who had the E157Q mutation and were initiated with DTG-based therapy did not experience viremia suppression below detection level.
Discussion: In a previous study conducted by, we also found E157Q on HIV-1-infected South African sequences retrieved from the HIV database.
Discussion: Viruses having E157Q were found to be associated with treatment failure of a DTG-containing regimen.
Discussion: We also identified the presence of E157Q in 2 (2%) patients.
HIV mutation literature information.
PMID: 
2020
Antimicrobial resistance and infection control
Browser Board
Co-occurred Entities
Filtrator
ViMRT